SCHEMBL5424944

SCHEMBL5424944

CC[C@H](CO)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 2/20 0.50
CCNA2 P20248 2/20 0.50
CDK2 P24941 2/20 0.50
CDK9 P50750 2/20 0.50
CDK5 Q00535 2/20 0.50
DYRK1A Q13627 2/20 0.50
CDK5R1 Q15078 2/20 0.50
DYRK2 Q92630 2/20 0.50
DYRK1B Q9Y463 2/20 0.50
DYRK3 O43781 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
MMP2 P08253 1/20 0.47
TRPV3 Q8NET8 4/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CDK1 P06493 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359412 1.00 CCNT1 (0.50) CCNT1CCNA2CDK2CDK9CDK5
SCHEMBL5766910 0.89 CA1 (0.49) CCNT1CCNA2CDK2CDK9CDK5
SCHEMBL1734544 0.81 CA12 (0.46) CA12CA1MMP2MEN1KMT2A
SCHEMBL14509044 0.81 CA12 (0.46) CA12CA1MMP2MEN1KMT2A
SCHEMBL1734546 0.81 CA12 (0.46) CA12CA1MMP2MEN1KMT2A
SCHEMBL8996214 0.80 KIF11 (0.45) CA12CA1MMP2MEN1KMT2A
SCHEMBL1937094 0.80 KIF11 (0.45) CA12CA1MMP2MEN1KMT2A
SCHEMBL3265463 0.80 KIF11 (0.45) CA12CA1MMP2MEN1KMT2A
SCHEMBL5129528 0.79 CA12 (0.41) CCNT1CCNA2CDK2CDK9CDK5
SCHEMBL5357329 0.79 CA12 (0.41) CCNT1CCNA2CDK2CDK9CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223870-B2 Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction PFIZER INC. (US) 2007-05-29 US disclosed
US-7223870-B2 Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction PFIZER INC. (US) 2007-05-29 US disclosed
US-20070049759-A1 Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling PFIZER INC 2007-03-01 US disclosed
US-20070049759-A1 Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling PFIZER INC 2007-03-01 US disclosed
US-20070049759-A1 Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling PFIZER INC 2007-03-01 US disclosed
EP-1562916-A1 METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION Pfizer Products Inc. (US) 2005-08-17 EP disclosed
WO-2004039788-A1 METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION PFIZER PRODUCTS INC. (US) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049759-A1 Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling AOC2, SOD1, AOC3 CCNT1 331/4885CCNA2 960/4885CDK2 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.